145 related articles for article (PubMed ID: 16951339)
1. Reduced susceptibility of recombinant polyclonal antibodies to inhibitory anti-variable domain antibody responses.
Klitgaard JL; Coljee VW; Andersen PS; Rasmussen LK; Nielsen LS; Haurum JS; Bregenholt S
J Immunol; 2006 Sep; 177(6):3782-90. PubMed ID: 16951339
[TBL] [Abstract][Full Text] [Related]
2. Structural correlates of an anticarcinoma antibody: identification of specificity-determining residues (SDRs) and development of a minimally immunogenic antibody variant by retention of SDRs only.
Tamura M; Milenic DE; Iwahashi M; Padlan E; Schlom J; Kashmiri SV
J Immunol; 2000 Feb; 164(3):1432-41. PubMed ID: 10640759
[TBL] [Abstract][Full Text] [Related]
3. Grafting of "abbreviated" complementarity-determining regions containing specificity-determining residues essential for ligand contact to engineer a less immunogenic humanized monoclonal antibody.
De Pascalis R; Iwahashi M; Tamura M; Padlan EA; Gonzales NR; Santos AD; Giuliano M; Schuck P; Schlom J; Kashmiri SV
J Immunol; 2002 Sep; 169(6):3076-84. PubMed ID: 12218124
[TBL] [Abstract][Full Text] [Related]
4. Molecular characterization of the anti-idiotypic immune response of a relapse-free neuroblastoma patient following antibody therapy: a possible vaccine against tumors of neuroectodermal origin?
Uttenreuther-Fischer MM; Krüger JA; Fischer P
J Immunol; 2006 Jun; 176(12):7775-86. PubMed ID: 16751426
[TBL] [Abstract][Full Text] [Related]
5. An anti-murine CD3 monoclonal antibody with a low affinity for Fc gamma receptors suppresses transplantation responses while minimizing acute toxicity and immunogenicity.
Alegre ML; Tso JY; Sattar HA; Smith J; Desalle F; Cole M; Bluestone JA
J Immunol; 1995 Aug; 155(3):1544-55. PubMed ID: 7636216
[TBL] [Abstract][Full Text] [Related]
6. Treatment of B-cell lymphoma with chimeric IgG and single-chain Fv antibody-interleukin-2 fusion proteins.
Liu SJ; Sher YP; Ting CC; Liao KW; Yu CP; Tao MH
Blood; 1998 Sep; 92(6):2103-12. PubMed ID: 9731068
[TBL] [Abstract][Full Text] [Related]
7. A therapeutic human anti-idiotypic antibody mimics CD55 in three distinct regions.
Spendlove L; Li L; Potter V; Christiansen D; Loveland BE; Durrant LG
Eur J Immunol; 2000 Oct; 30(10):2944-53. PubMed ID: 11069077
[TBL] [Abstract][Full Text] [Related]
8. Molecular dissection of antibody responses against pneumococcal surface protein A: evidence for diverse DH-less heavy chain gene usage and avidity maturation.
Rohatgi S; Dutta D; Tahir S; Sehgal D
J Immunol; 2009 May; 182(9):5570-85. PubMed ID: 19380805
[TBL] [Abstract][Full Text] [Related]
9. Molecular modeling of an anti-DNA autoantibody (V-88) and mapping of its V region epitopes recognized by heterologous and autoimmune antibodies.
Hobby P; Ward FJ; Denbury AN; Williams DG; Staines NA; Sutton BJ
J Immunol; 1998 Sep; 161(6):2944-52. PubMed ID: 9743357
[TBL] [Abstract][Full Text] [Related]
10. Specific lysis of melanoma cells by receptor grafted T cells is enhanced by anti-idiotypic monoclonal antibodies directed to the scFv domain of the receptor.
Reinhold U; Liu L; Lüdtke-Handjery HC; Heuser C; Hombach A; Wang X; Tilgen W; Ferrone S; Abken H
J Invest Dermatol; 1999 May; 112(5):744-50. PubMed ID: 10233766
[TBL] [Abstract][Full Text] [Related]
11. Elimination of the immunogenicity of therapeutic antibodies.
Gilliland LK; Walsh LA; Frewin MR; Wise MP; Tone M; Hale G; Kioussis D; Waldmann H
J Immunol; 1999 Mar; 162(6):3663-71. PubMed ID: 10092828
[TBL] [Abstract][Full Text] [Related]
12. Analysis of BR96 binding sites for antigen and anti-idiotype by codon-based scanning mutagenesis.
Rosok MJ; Eghtedarzadeh-Kondri M; Young K; Bajorath J; Glaser S; Yelton D
J Immunol; 1998 Mar; 160(5):2353-9. PubMed ID: 9498776
[TBL] [Abstract][Full Text] [Related]
13. The antigen binding domain of non-idiotypic human anti-F(ab')2 autoantibodies: study of their interaction with IgG hinge region epitopes.
Welschof M; Reineke U; Kleist C; Kipriyanov S; Little M; Volkmer-Engert R; Schneider-Mergener J; Opelz G; Terness P
Hum Immunol; 1999 Apr; 60(4):282-90. PubMed ID: 10363719
[TBL] [Abstract][Full Text] [Related]
14. Identification of epitope regions recognized by tumor inhibitory and stimulatory anti-ErbB-2 monoclonal antibodies: implications for vaccine design.
Yip YL; Smith G; Koch J; Dübel S; Ward RL
J Immunol; 2001 Apr; 166(8):5271-8. PubMed ID: 11290813
[TBL] [Abstract][Full Text] [Related]
15. Chimeric anti-N-glycolyl-ganglioside and its anti-idiotypic MAbs: immunodominance of their variable regions.
López-Requena A; Mateo de Acosta C; Pérez A; Valle A; Lombardero J; Sosa K; Pérez R; Vázquez AM
Hybrid Hybridomics; 2003 Aug; 22(4):235-43. PubMed ID: 14511569
[TBL] [Abstract][Full Text] [Related]
16. Protective immunization against group B meningococci using anti-idiotypic mimics of the capsular polysaccharide.
Beninati C; Arseni S; Mancuso G; Magliani W; Conti S; Midiri A; Biondo C; Polonelli L; Teti G
J Immunol; 2004 Feb; 172(4):2461-8. PubMed ID: 14764718
[TBL] [Abstract][Full Text] [Related]
17. "Superhumanized" antibodies: reduction of immunogenic potential by complementarity-determining region grafting with human germline sequences: application to an anti-CD28.
Tan P; Mitchell DA; Buss TN; Holmes MA; Anasetti C; Foote J
J Immunol; 2002 Jul; 169(2):1119-25. PubMed ID: 12097421
[TBL] [Abstract][Full Text] [Related]
18. DNA vaccines against lymphoma: promotion of anti-idiotypic antibody responses induced by single chain Fv genes by fusion to tetanus toxin fragment C.
Spellerberg MB; Zhu D; Thompsett A; King CA; Hamblin TJ; Stevenson FK
J Immunol; 1997 Aug; 159(4):1885-92. PubMed ID: 9257853
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-6 fused to an anti-idiotype antibody in a vaccine increases the specific humoral immune response against CA125+ (MUC-16) ovarian cancer.
Reinartz S; Hombach A; Köhler S; Schlebusch H; Wallwiener D; Abken H; Wagner U
Cancer Res; 2003 Jun; 63(12):3234-40. PubMed ID: 12810653
[TBL] [Abstract][Full Text] [Related]
20. CDR substitutions of a humanized monoclonal antibody (CC49): contributions of individual CDRs to antigen binding and immunogenicity.
Iwahashi M; Milenic DE; Padlan EA; Bei R; Schlom J; Kashmiri SV
Mol Immunol; 1999; 36(15-16):1079-91. PubMed ID: 10698310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
